MRUS - Merus N.V.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
15.89
-0.26 (-1.61%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close16.15
Open16.64
Bid0.00 x 2900
Ask0.00 x 800
Day's Range15.05 - 16.82
52 Week Range11.00 - 26.74
Volume43,865
Avg. Volume32,475
Market Cap371.175M
Beta (3Y Monthly)-0.03
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • GlobeNewswire22 days ago

    Merus Announces Financial Results for the Full Year 2018 and Provides Business Update

    UTRECHT, The Netherlands, April 03, 2019 -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®,.

  • GlobeNewswire24 days ago

    Merus and Incyte Present MCLA-145 Program Preclinical Data at the AACR Annual Meeting 2019

    Merus N.V. (MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific antibody therapeutics, and in collaboration with Incyte (INCY), presented preclinical data from the MCLA-145 program at the American Association for Cancer Research (AACR) Annual Meeting 2019 in Atlanta, GA. Merus and Incyte presented two posters outlining preclinical data on MCLA-145, the Biclonics® program targeting CD137 and PD-L1, on Sunday, March 31.

  • GlobeNewswirelast month

    Merus to Present at the Cowen & Co. 39th Annual Health Care Conference

    UTRECHT, Netherlands, March 11, 2019 -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®,.

  • GlobeNewswire3 months ago

    Merus to Participate in Guggenheim Healthcare Talks Idea Forum

    UTRECHT, Netherlands, Feb. 07, 2019 -- Merus N.V. (Nasdaq: MRUS), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human bispecific.

  • GlobeNewswire4 months ago

    Merus Announces IND Clearance for MCLA-145

    “We are pleased to announce the IND authorization to proceed from the FDA and to disclose more details around our latest Biclonics® program today,” said Andres Sirulnik, M.D., Ph. D., Executive Vice President and Chief Medical Officer of Merus. “Our preclinical work has demonstrated that MCLA-145 has the potential to overcome the known side effects of CD137 agonists currently in development and to address a significant unmet need in patient populations not benefitting from current immunotherapeutic agents. Discovered through an unbiased functional screening of multiple immunomodulatory target combinations, MCLA-145 is a Biclonics® T-cell agonist that binds with high affinity and specificity to human PD-L1 and CD137 in preclinical models.

  • CNW Group4 months ago

    ProBioGen's GlymaxX® ADCC Enhancement Technology Used by Betta Pharmaceuticals

    ProBioGen's GlymaxX® ADCC Enhancement Technology Used by Betta Pharmaceuticals

  • GlobeNewswire4 months ago

    Merus Announces Strategic Collaboration with Betta Pharmaceuticals to Develop and Commercialize MCLA-129 in China

    Merus to retain all global rights outside of ChinaBetta Pharmaceuticals to fund global IND-enabling activities UTRECHT, the Netherlands, Jan. 02, 2019 -- Merus N.V. (Nasdaq:.

  • GlobeNewswire4 months ago

    Merus Announces Financial Results for the Third Quarter 2018 and Provides Business Update

    Clinical milestones for four lead Biclonics® programs expected in 2019Cash expected to be sufficient to fund operations into the second quarter of 2021 UTRECHT, The.

  • GlobeNewswire4 months ago

    Merus Announces Global Settlement and End to All Patent Litigation with Regeneron Pharmaceuticals

    Merus N.V. (MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced a settlement of all pending patent litigation and administrative proceedings between Merus and Regeneron Pharmaceuticals, Inc. pertaining to certain antibody generation platforms of each company. As part of the settlement, both parties have signed a global patent cross-license agreement, and Regeneron has agreed to provide an investment in Merus of $15 million through the purchase of 600,000 common shares at a price of $25 per share representing a premium of 118% from the close of trading on December 20, 2018.

  • GlobeNewswire6 months ago

    Merus to Present at the Jefferies 2018 London Healthcare Conference

    UTRECHT, The Netherlands, Nov. 08, 2018 -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics.

  • GlobeNewswire9 months ago

    Merus N.V. : Merus Announces Recent Corporate Developments and Financial Results for the First Quarter 2018

    - Initiation of Phase 1, first-in-human clinical trial of MCLA-158 in patients with solid tumors - - MCLA-128`s unique mechanism of action published in the scientific journal Cancer Cell - UTRECHT, The ...

  • GlobeNewswire10 months ago

    Merus Announces Annual Meeting of Shareholders

    Merus N.V. (MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the Annual General Meeting of Shareholders will be held on Friday, July 20, 2018 at 8:00 a.m. CEST, at the offices of NautaDutilh N.V. (address: Beethovenstraat 400, 1082 PR Amsterdam, the Netherlands). All relevant documents and information for the meeting, including the notice and agenda, are available in the `Investor Relations` section of Merus` website (www.merus.nl) under "Financial Information". Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®.

  • GlobeNewswire11 months ago

    Merus to Present at the Jefferies 2018 Healthcare Conference

    UTRECHT, The Netherlands, May 31, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics ® ), today ...